ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.283,62
0,20%
S&P 500
5.297,10
-0,21%
US Dollar vs BRL
5,1303
0,00%
Bitcoin
65.311,49
0,11%
Brent Oil
83,135
-0,08%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Natera Inc (NTRA)

  7. Natera Inc (NTRA) Notícias

NTRA

Natera (NTRA)

Natera Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NTRA
DataHoraFonteTítuloCódigoCompanhia
15/05/202417:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
10/05/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
09/05/202417:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTRANatera Inc
09/05/202417:05Business WireNatera Reports First Quarter 2024 Financial ResultsNASDAQ:NTRANatera Inc
03/05/202409:00Business WireNew Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast CancerNASDAQ:NTRANatera Inc
01/05/202417:05Business WireNatera to Report its First Quarter 2024 Results on May 9NASDAQ:NTRANatera Inc
01/05/202408:00Business WireNatera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg ShortageNASDAQ:NTRANatera Inc
22/04/202409:00Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsNASDAQ:NTRANatera Inc
11/04/202409:00Business WireNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationNASDAQ:NTRANatera Inc
08/04/202409:00Business WireNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsNASDAQ:NTRANatera Inc
05/04/202408:00Business WireNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerNASDAQ:NTRANatera Inc
01/04/202409:00Business WireNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerNASDAQ:NTRANatera Inc
18/03/202408:00Business WireNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerNASDAQ:NTRANatera Inc
14/03/202409:00Business WireNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseNASDAQ:NTRANatera Inc
12/03/202409:00Business WireNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersNASDAQ:NTRANatera Inc
07/03/202410:00Business WireNatera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanNASDAQ:NTRANatera Inc
29/02/202410:00Business WireNatera to Participate in March Investor ConferencesNASDAQ:NTRANatera Inc
28/02/202418:05Business WireNatera Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NTRANatera Inc
27/02/202410:00Business WireNatera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure TestsNASDAQ:NTRANatera Inc
26/02/202409:00Business WireMedicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast CancerNASDAQ:NTRANatera Inc
20/02/202410:00Business WireNatera Announces Fourth Quarter and Fiscal 2023 Earnings Conference CallNASDAQ:NTRANatera Inc
05/02/202410:00Business WireNew Study Validates Signatera™ in Endometrial CancerNASDAQ:NTRANatera Inc
30/01/202423:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTRANatera Inc
30/01/202409:00Business WireNew Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung CancerNASDAQ:NTRANatera Inc
29/01/202409:00Business WireJury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past RoyaltiesNASDAQ:NTRANatera Inc
25/01/202409:00Business WireNature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal MalignanciesNASDAQ:NTRANatera Inc
22/01/202409:00Business WireNatera Acquires Reproductive Health Assets from InvitaeNASDAQ:NTRANatera Inc
22/01/202409:00PR Newswire (US)Invitae Completes Sale of Reproductive Health Assets to NateraNASDAQ:NTRANatera Inc
18/01/202410:00Business WireNatera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRCNASDAQ:NTRANatera Inc
16/01/202419:17Business WireNatera Provides Update on Ravgen TrialNASDAQ:NTRANatera Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NTRA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HBOR3
HELBOR ON
BOV
BRSR6
BANRISUL PNB
BOV
GFSA3
GAFISA ON
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados